- Trial phase
- Approved
- Time to market
- Already marketed (FDA-approved November 2021)
- Why 3/10
- No upcoming PDUFA date, AdComm, or pivotal topline readout is scheduled for LIVTENCITY in the next 12 months; the drug is already approved and commercialized, and Takeda is a large diversified pharma, so this drug alone will not drive a binary stock move.
Watch for updates in Takeda's patent litigation against Qilu Pharmaceutical (ANDA filed 2026) which could affect LIVTENCITY's generic timeline; also monitor quarterly sales growth rate and any label expansion progress for first-line CMV treatment. The drug's next material catalyst would be a successful front-line indication trial, but none is currently on a near-term regulatory calendar.
Price Chart
Executive Summary
LIVTENCITY (maribavir) is Takeda's first-in-class oral antiviral for post-transplant cytomegalovirus (CMV) infection that is refractory to standard therapies. FDA-approved in November 2021 and now available in 30+ countries including Japan, the drug holds a unique niche as the only approved treatment for resistant/refractory post-transplant CMV. Sales reached JPY 14.1 billion (~$93M) in Q1 FY2026, growing 21% year-over-year, implying a ~$370M annual run rate. However, it represents only about 1.25% of Takeda's total revenue, and the AURORA Phase 3 trial for a larger first-line indication failed in 2022. NCE exclusivity expired in November 2025, and Takeda is now in patent litigation with generic challenger Qilu Pharmaceutical. With no upcoming PDUFA or pivotal readout, the drug is a steady commercial performer but not a near-term binary catalyst for Takeda shares.
How It Works
LIVTENCITY is an antiviral pill that treats cytomegalovirus (CMV), a common herpes-family virus that can cause serious illness in organ or stem cell transplant patients. It works by blocking a specific CMV enzyme (pUL97 kinase) that the virus needs to replicate, stopping the infection from spreading. It is taken orally twice a day.
Trial Status
Approved based on the pivotal Phase 3 SOLSTICE trial. A Phase 3 study for front-line CMV treatment (AURORA) missed its primary endpoint. A Phase 3 study in Chinese adults with CMV infections completed in July 2026. Multiple real-world evidence and post-marketing studies are ongoing.
The Two-Sided Case
Upcoming Catalysts
- Patent litigation outcome against Qilu Pharmaceutical (ANDA challenge, ongoing) could affect generic entry timeline
- Quarterly sales growth trajectory in Takeda earnings reports
- Any future data from label-expansion trials for first-line CMV treatment
- Potential additional geographic approvals or launches
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report